Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cara Martin

Showing results (21-30 of 46) with videos related to

Pageof 5
Sort By:
Journal of Proteomics|March 15, 2012
Epitope presentation is an important determinant of the utility of antigens identified from protein arrays in the development of autoantibody diagnostic assaysMairead A Murphy, David J O'Connell, Sara L O'Kane, et al.
Nature Immunology|December 1, 2009
Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21Frederick J Sheedy, Eva Palsson-McDermott, Elizabeth J Hennessy, et al.
Journal of Clinical Pathology|June 4, 2015
Enhanced regulation of cell cycle and suppression of osteoblast differentiation molecular signatures by prostate cancer stem-like holoclonesMichael F Gallagher, Yvonne Salley, Cathy D Spillane, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 1, 2012
TLR9 provokes inflammation in response to fetal DNA: mechanism for fetal loss in preterm birth and preeclampsiaAndrea Scharfe-Nugent, Sinéad C Corr, Susan B Carpenter, et al.
Cancer Letters|December 3, 2014
A novel serum microRNA panel to discriminate benign from malignant ovarian diseaseReam Langhe, Lucy Norris, Feras Abu Saadeh, et al.
Biochimica Et Biophysica Acta. Reviews on Cancer|February 16, 2023
Circulating tumour cells: The Good, the Bad and the UglyMark Bates, Bashir M Mohamed, Mark P Ward, et al.
Plos One|December 28, 2020
The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancerMark Bates, Cathy D Spillane, Michael F Gallagher, et al.
Cells|October 28, 2025
Crosstalk Between Inflammasome Signalling and Epithelial-Mesenchymal Transition in Cancer and Benign Disease: Mechanistic Insights, Context-Dependence, and Therapeutic OpportunitiesAbdul L Shakerdi, Emma Finnegan, Yin-Yin Sheng, et al.
Molecular Cancer|April 30, 2008
Potential role of miR-9 and miR-223 in recurrent ovarian cancerAlexandros Laios, Sharon O'Toole, Richard Flavin, et al.
The Journal of Pathology|November 10, 2011
Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancerFiona Furlong, Patricia Fitzpatrick, Sharon O'Toole, et al.
Pageof 5

Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
Journal of Proteomics|March 15, 2012
Epitope presentation is an important determinant of the utility of antigens identified from protein arrays in the development of autoantibody diagnostic assaysMairead A Murphy, David J O'Connell, Sara L O'Kane, et al.
Nature Immunology|December 1, 2009
Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21Frederick J Sheedy, Eva Palsson-McDermott, Elizabeth J Hennessy, et al.
Journal of Clinical Pathology|June 4, 2015
Enhanced regulation of cell cycle and suppression of osteoblast differentiation molecular signatures by prostate cancer stem-like holoclonesMichael F Gallagher, Yvonne Salley, Cathy D Spillane, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 1, 2012
TLR9 provokes inflammation in response to fetal DNA: mechanism for fetal loss in preterm birth and preeclampsiaAndrea Scharfe-Nugent, Sinéad C Corr, Susan B Carpenter, et al.
Cancer Letters|December 3, 2014
A novel serum microRNA panel to discriminate benign from malignant ovarian diseaseReam Langhe, Lucy Norris, Feras Abu Saadeh, et al.
Biochimica Et Biophysica Acta. Reviews on Cancer|February 16, 2023
Circulating tumour cells: The Good, the Bad and the UglyMark Bates, Bashir M Mohamed, Mark P Ward, et al.
Plos One|December 28, 2020
The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancerMark Bates, Cathy D Spillane, Michael F Gallagher, et al.
Cells|October 28, 2025
Crosstalk Between Inflammasome Signalling and Epithelial-Mesenchymal Transition in Cancer and Benign Disease: Mechanistic Insights, Context-Dependence, and Therapeutic OpportunitiesAbdul L Shakerdi, Emma Finnegan, Yin-Yin Sheng, et al.
Molecular Cancer|April 30, 2008
Potential role of miR-9 and miR-223 in recurrent ovarian cancerAlexandros Laios, Sharon O'Toole, Richard Flavin, et al.
The Journal of Pathology|November 10, 2011
Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancerFiona Furlong, Patricia Fitzpatrick, Sharon O'Toole, et al.
Pageof 5